NIH-funded research R01 grant

How gut bacteria affect cancer treatment effectiveness

Official title: Improvement of cellular immunotherapy during dysbiosis- Resubmission

Funded at Univ of Arkansas for Med Scis · NIH-10916290 · Data updated 2026-11-12

This study is looking at how changes in gut bacteria caused by antibiotics might affect the success of cancer treatments for melanoma, and it's especially for patients with advanced melanoma who have taken antibiotics.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniv of Arkansas for Med Scis
NIH-funded
Lab location1 site (Little Rock, United States)
Project startSeptember 15, 2021
Project endAugust 31, 2026
Funding year2024
Award (this year)$332,749
NIH project number5R01CA245083-04
Project IDNIH-10916290 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research are melanoma patients who have received antibiotics and are undergoing or considering cellular immunotherapy.

Less likely to help

Patients who have not received antibiotics or those with early-stage melanoma may not benefit from this research.

What this research studies

This research investigates the impact of antibiotic-induced changes in gut bacteria, known as dysbiosis, on the effectiveness of cellular immunotherapy for melanoma patients. The study aims to understand how these changes in the gut microbiome can influence the immune response to cancer treatments. By focusing on the relationship between dysbiosis and the tumor microenvironment, the researchers hope to develop strategies to enhance the efficacy of immunotherapy. Patients with advanced melanoma who have undergone antibiotic treatment may particularly benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to improved outcomes for melanoma patients receiving cellular immunotherapy by addressing the negative effects of dysbiosis.

How similar studies have gone: Other research has shown promising results in understanding the role of the gut microbiome in cancer treatment, suggesting that this approach could yield significant insights.

Where this research is happening

  • Univ of Arkansas for Med Scis
    Little Rock, United States
    Active

Researchers

  • Principal investigator: Dings, Ruud P.m. — Univ of Arkansas for Med Scis
  • Study coordinator: Dings, Ruud P.m.

Related research

Other NIH-funded projects on the same topics.

  • Improving cell-based melanoma treatment affected by antibiotic-related gut imbalance

    Working to make cell-based immunotherapy work better for people with advanced melanoma whose gut bacteria were disrupted by antibiotics.

    NIH research Univ of Arkansas for Med Scis · Little Rock, United States · NIH-11211211

  • Improving immune cell therapy for melanoma after antibiotic-related gut changes

    This work seeks ways to help cellular immunotherapy work better for people with melanoma whose gut bacteria have been disrupted by antibiotics.

    NIH research Univ of Arkansas for Med Scis · Little Rock, United States · NIH-11171417

  • How gut bacteria affect cancer treatment effectiveness

    This study is looking at how changes in gut bacteria caused by antibiotics might affect the success of immunotherapy for patients with advanced melanoma, with the hope of finding ways to improve treatment results for those who need it.

    NIH research Univ of Arkansas for Med Scis · Little Rock, United States · NIH-11059705

  • Boosting immune response to fight cancer

    This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.

    NIH research University of Missouri-Columbia · Columbia, United States · NIH-9868156

  • A center focused on immunotherapy for pediatric cancers.

    This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.

    NIH research Research Inst Nationwide Children's Hosp · Columbus, United States · NIH-9839924

  • Microbial Dysbiosis and Its Role in Pancreatic Cancer

    A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.

    NIH research Northwestern University · Chicago, United States · NIH-11624054

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.